Acelyrin Inc. announced on May 21, 2025, that it has completed a merger resulting in a change of control, making it a wholly owned subsidiary of Alumis. As part of this transition, Acelyrin notified Nasdaq of the merger's completion and requested the suspension of its common stock trading. The company plans to delist its stock from Nasdaq and deregister under the Securities Exchange Act of 1934. Additionally, Acelyrin intends to terminate its reporting obligations under the Exchange Act. This regulatory change is accompanied by the termination of its 2023 Employee Stock Purchase Plan.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.